Technical Analysis for PIRS - Pieris Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade A 4.41 17.60% 0.66
PIRS closed up 17.6 percent on Friday, May 24, 2019, on 5.41 times normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical PIRS trend table...

Date Alert Name Type % Chg
Crossed Above 200 DMA Bullish 0.00%
Expansion Breakout Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Wide Range Bar Range Expansion 0.00%
Parabolic Rise Strength 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
200 DMA Resistance Bearish 17.60%

Older signals for PIRS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of Anticalin class biotherapeutics. Anticalin proteins are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company primarily focuses on development of two drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; and PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases. It is also developing PRS-110, a monovalent antagonist that is used for the treatment of various types of cancers, including renal, gastric, and lung carcinomas, as well as central nervous system tumors and sarcomas; and PRS-300series of Anticalin proteins in immuno-oncology. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany.
Medicine Chemistry Cancers Dialysis Asthma Chronic Kidney Disease Membrane Technology Inflammatory Diseases Anatomy End Stage Renal Disease Kidney Diseases Hepatology Kidney Hepcidin Treatment Of Various Types Of Cancers
Is PIRS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 6.55
52 Week Low 2.39
Average Volume 378,370
200-Day Moving Average 3.7725
50-Day Moving Average 3.327
20-Day Moving Average 3.4555
10-Day Moving Average 3.784
Average True Range 0.2996
ADX 32.3
+DI 41.9077
-DI 11.4391
Chandelier Exit (Long, 3 ATRs ) 3.7812
Chandelier Exit (Short, 3 ATRs ) 3.7288
Upper Bollinger Band 4.2077
Lower Bollinger Band 2.7033
Percent B (%b) 1.13
BandWidth 43.536391
MACD Line 0.206
MACD Signal Line 0.1334
MACD Histogram 0.0726
Fundamentals Value
Market Cap 195.4 Million
Num Shares 44.3 Million
EPS -0.71
Price-to-Earnings (P/E) Ratio -6.21
Price-to-Sales 31.97
Price-to-Book 22.72
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.78
Resistance 3 (R3) 5.71 5.20 5.55
Resistance 2 (R2) 5.20 4.85 5.23 5.47
Resistance 1 (R1) 4.80 4.63 5.00 4.87 5.40
Pivot Point 4.29 4.29 4.39 4.32 4.29
Support 1 (S1) 3.89 3.94 4.09 3.96 3.42
Support 2 (S2) 3.38 3.72 3.41 3.35
Support 3 (S3) 2.98 3.38 3.27
Support 4 (S4) 3.05